Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06440005 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Angiex.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 6
- Study locations
NCT06440005: Recruiting Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Angiex.
NCT06440005 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by Angiex. The registered enrollment target is 80 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06440005, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by Angiex.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 6
- Study locations
Study Summary
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study drug.
Primary Outcome
Maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of AGX101 will be characterized
Conditions Studied
Interventions
- DRUG AGX101
Study Locations (6)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
Florida
- Florida Cancer Specialist - Sarasota
Missouri
- Washington University School of Medicine - St Louis
Tennessee
- Sarah Cannon Research Center - Nashville
Texas
- NEXT Oncology - San Antonio
Virginia
- NEXT Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-07-22 |
| Est. Completion | 2027-09-06 |
| Phase | Phase 1 |
What NCT06440005 shows while recruiting
NCT06440005 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AGX101 is the first listed.
NCT06440005 lists 6 locations in 6 states (California, Florida, Missouri).
Frequently Asked Questions
What is clinical trial NCT06440005 about?
NCT06440005 is a clinical study titled "A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors". AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re...
What is the current status of trial NCT06440005?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-07-22. Estimated completion is 2027-09-06.
What conditions does trial NCT06440005 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Cancer, Colorectal Cancer, Pancreatic Cancer.
What interventions are being tested in trial NCT06440005?
The interventions under investigation include: AGX101 (DRUG).
Who is sponsoring clinical trial NCT06440005?
This trial is sponsored by Angiex, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06440005 being conducted?
This trial has 6 study locations across California, Florida, Missouri, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06440005's enrollment target sits among peer trials
80 649th of 1224 higher than 566 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI